The company focuses on the unmet medical needs of patients with serious diseases. Its product line includes chemically-synthesized drugs and biological products, which focus on areas like cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/AIDS and rheumatoid arthritis (GlobalData, 2014). This research analyzed the internal weakness of Bristol-Myers Squibb. The internal weakness reveal losses in patent protection, lawsuits and decline in revenues due to a lack in leadership and poor managerial decision making. Research showed that BMS patent loss for some of its major seller drugs include Plavix, Abilify and Avapro lead to a huge plunge in revenues. In 2012, Avapro revenues decline by 17 percent to $17.6 billion (Hoovers, 2015). In comparison, Abilify accounted for about $1.54 billion in revenues the first nine months in 2014 (Trefis,
The company focuses on the unmet medical needs of patients with serious diseases. Its product line includes chemically-synthesized drugs and biological products, which focus on areas like cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/AIDS and rheumatoid arthritis (GlobalData, 2014). This research analyzed the internal weakness of Bristol-Myers Squibb. The internal weakness reveal losses in patent protection, lawsuits and decline in revenues due to a lack in leadership and poor managerial decision making. Research showed that BMS patent loss for some of its major seller drugs include Plavix, Abilify and Avapro lead to a huge plunge in revenues. In 2012, Avapro revenues decline by 17 percent to $17.6 billion (Hoovers, 2015). In comparison, Abilify accounted for about $1.54 billion in revenues the first nine months in 2014 (Trefis,